Characteristics | Antimuscarinic | |||
---|---|---|---|---|
Fesoterodine | Solifenacin | Tolterodine | Overall | |
(n = 302) | (n = 952) | (n = 717) | PValue | |
Demographics | ||||
Mean age, years (SD) | 67.5 (11.0) | 69.7 (10.8)* | 71.7 (9.8)*† | <0.001 |
Female, n (%) | 156 (51.7) | 562 (59.0) | 432 (60.3)‡ | 0.036 |
Retired, n (%) | 254 (84.1) | 836 (87.8) | 673 (93.8)*† | <0.001 |
Burden of comorbidity | ||||
Associated diagnoses, n (%) | 2.6 (1.7) | 2.8 (1.7) | 2.8 (1.5) | 0.135 |
Charlson comorbidity index, mean (SD) | 1.2 (1.3) | 1.2 (1.3) | 1.3 (1.4) | 0.230 |
Score, n (%) | 0.326 | |||
0–1 | 228 (75.5) | 703 (73.8) | 516 (72.0) | |
2–3 | 50 (16.6) | 166 (17.4) | 120 (16.7) | |
≥4 | 24 (7.9) | 83 (8.7) | 81 (11.3) | |
Associated co-morbidities, n (%) | ||||
Hypertension | 142 (47.0) | 494 (51.9) | 413 (57.6)‡ | 0.004 |
Diabetes | 62 (20.5) | 233 (24.5) | 178 (24.5) | 0.304 |
Dyslipidemia | 148 (49.0) | 454 (47.7) | 385 (53.7)‡ | 0.048 |
Obesity | 66 (21.9) | 204 (21.4) | 147 (20.5) | 0.854 |
Active smoker | 44 (14.6) | 140 (14.7) | 69 (9.6)†‡ | 0.006 |
Alcoholism | 13 (4.3) | 22 (2.3) | 16 (2.2) | 0.124 |
Ischemic heart disease | 34 (11.3) | 114 (12.0) | 77 (10.7) | 0.731 |
Cerebrovascular accident | 44 (14.6) | 135 (14.2) | 119 (16.6) | 0.378 |
Organ failure | 34 (11.3) | 132 (13.9) | 87 (12.1) | 0.389 |
Bronchial asthma | 32 (10.6) | 104 (10.9) | 64 (8.9) | 0.393 |
COPD | 34 (11.3) | 125 (13.1) | 93 (13.0) | 0.685 |
Dementia (all types) | 25 (8.3) | 88 (9.2) | 78 (10.9) | 0.357 |
Neuropathies | 33 (10.9) | 100 (10.5) | 82 (11.4) | 0.833 |
Depressive syndrome | 20 (6.6) | 86 (9.0) | 69 (9.6) | 0.298 |
Malignant neoplasms | 64 (21.2) | 216 (22.7) | 159 (22.3) | 0.862 |
Treatment duration and dose, mean (SD) | ||||
Time since OAB diagnosis, years | 4.4 (1.8) | 4.8 (1.9)‡ | 4.5 (1.8)§ | 0.023 |
Observed treatment duration, weeks | 35.5 (17.6) | 33.9 (21.4) | 33.0 (21.6) | 0.160 |
Medication possession ratio, % | 94.5 (8.4) | 95.4 (8.3) | 94.6 (8.7) | 0.053 |
Number of antimuscarinics‖ | 1.0 (0.2) | 1.0 (0.2) | 1.1 (0.3)§ | <0.001 |
Antimuscarinic dose, n (%) | ||||
2 mg | 86 (12.0) | |||
4 mg | 131 (43.4) | --- | 631 (88.0) | |
8 mg | 171 (56.6) | --- | --- | |
5 mg | --- | 828 (87.0) | --- | |
10 mg | --- | 74 (13.0) | --- |